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Abstract
Introduction: Sepsis is characterized by systemic microvascular dysfunction. Endothelial progenitor cells (EPCs) are
critically involved in maintaining vascular homeostasis under both physiological and pathological conditions. The
aim of the present study was to analyze the endothelial progenitor cell system in patients suffering from sepsis
with acute renal dysfunction.
Methods: Patients with newly diagnosed sepsis were recruited from the ICU in a nonrandomized prospective manner.
Blood samples were obtained within the first 12 hours after the diagnosis of sepsis. For quantifying endothelial
progenitor cells (EPCs), CD133
+/Flk-1
+ cells were enumerated by cytometric analysis. Analysis of EPC proliferation was
performed by a colony-forming units (CFU) assay. Blood concentrations of proangiogenic mediators were measured by
ELISA. Acute renal dysfunction was diagnosed according to the Acute Kidney Injury Network (AKIN) criteria. Depending
on the overall mean creatinine concentration during the stay at the ICU, patients were either assigned to a ‘normal
creatinine group’ or to a ‘high creatinine group’. Survival rates, frequency of dialysis, the simplified acute physiology
score (SAPS) II scores, and different laboratory parameters were collected/used for further clinical characterization
Results: Circulating EPCs were significantly higher in all sepsis patients included in the study as opposed to healthy
controls. Patients within the ‘high creatinine group’ showed an even more pronounced EPC increase. In contrast, EPC
proliferation was severely affected in sepsis. Neither total circulating EPCs nor EPC proliferation differed between
patients requiring dialysis and patients without renal replacement therapy. Cell numbers and cell proliferation also did
not differ between surviving patients and patients with sepsis-related death. Serum levels of vascular endothelial
growth factor (VEGF), stromal derived factor-1 (SDF-1), and Angiopoietin-2 were higher in sepsis than in healthy
controls. Sepsis patients within the ‘high creatinine group’ showed significantly higher mean serum levels of uric acid.
Conclusions: Sepsis significantly affects the endothelial progenitor cell system, as reflected by increased EPC
numbers, increased concentrations of proangiogenic mediators, and reduced proliferative capacity of the cells. This
occurs independently from the frequency of dialysis and from patient survival. Increased serum levels of uric acid
are possibly responsible for stronger EPC mobilization in sepsis patients with higher average creatinine levels.
Introduction
Sepsis, defined as systemic inflammatory response
syndrome of infectious origin [1], is characterized by
systemic microvascular dysfunction [2,3]. Possible conse-
quences involve reduced microvascular blood flow,
thrombocyte aggregation, and activation of coagulation
[4,5]. Finally, severe organ failure can occur [6].
Endothelial progenitor cells (EPCs), although hetero-
genous in phenotypical and biological properties [7-10],
are critically involved in maintaining vascular homeosta-
sis and in mediating macro- and microvascular repair
under both physiological and pathological conditions
[11-14]. This has been documented in numerous experi-
mental and clinical studies over the past 10 years
[11,12,15,16]: impaired endothelial progenitor cell prolif-
eration has been shown in patients with macrovascular
damage such as coronary artery and cerebrovascular dis-
ease [15,17]. Patients with chronic renal failure, which
are at higher risk for artherosclerosis than healthy
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EPCs [18]. In acute ischemic renal failure, which is char-
acterized by postischemic hypoperfusion of peritubular
capillaries, renal function could be preserved by systemic
administration of both mature endothelial cells and
endothelial progenitor cells [16,19]. EPCs have also been
documented to be involved in glomerular endothelial
repair: bone marrow transplantation experiments in ani-
mals suffering from experimental glomerulonephritis
(’Thy-1 glomerulonephritis’) revealed that relevant num-
bers of damaged glomerular endothelial cells are replaced
by bone marrow-derived cells [20,21]. In addition, EPCs
have been proven to actively mediate endothelial regen-
eration in a model of thrombotic microangiopathy [22].
Finally, the cells have been documented to mediate repair
of damaged renal tissue in acute ischemic renal failure
[16,23,24]. It could be shown that tubular epithelial
damage can be prevented by systemic administration of
EPCs in such a situation [24].
Two newer studies reported increased peripheral
endothelial progenitor cells in patients suffering from
sepsis [25,26]. Cell numbers correlated with survival [26]
and severity of the disease [25]. Nevertheless, the
authors did not particularly analyze the possible impact
of sepsis-associated acute renal dysfunction on EPC pro-
liferation and total numbers of circulating EPCs. There-
fore, the aim of the present study was to analyze the
endothelial progenitor cell system in patients suffering
from sepsis with acute impairment of renal function.
Materials and methods
Patients and blood samples
Blood samples were obtained from 40 patients with sep-
sis in a nonrandomized prospective manner. Sepsis was
defined as systemic inflammatory response syndrome
(SIRS) of infectious origin [1]. Therefore, beside fulfilling
the criteria of SIRS [6], all patients showed at least one
positive blood culture for either Gram-positive or
Gram-negative bacteria. Patients with pre-existing ESRD
(end stage renal disease) were not included in the study.
This was of particular importance since previous studies
showed reduced EPC proliferation in uremic patients
[18]. All patients were recruited at the intensive care
unit over a period of 15 months. The study protocol
was approved after review by the local ethics committee.
The investigation conformed to the principles outlined
in the Declaration of Helsinki and written informed
consent was obtained from each subject. Healthy, age-
and gender-matched individuals served as controls. For
the studies, each patient (and the respective controls)
provided four blood samples (7.5 ml each), from which
two (2 × 7.5 ml) were used for endothelial and myelo-
monocytic cell studies, and two (2 × 7.5 ml) were used
for performing routine laboratory (see biochemical and
hematological tests) as well as immunological studies.
For quantifying renal function, urine was collected over
a period of 24 hours and creatinine clearance was calcu-
lated according to the formula by Cockcroft-Gault [27].
The severity of acute renal damage, if present, was eval-
uated using the AKIN (Acute Kidney Injury Network)
criteria. All blood samples w e r ed r a w nw i t h i n1 2h o u r s
after the diagnosis of sepsis. For further clinical charac-
terization different parameters, such as C-reactive pro-
tein and the SAPS (Simplified Acute Physiology Score)
II scores, were documented at the time blood was
drawn. In addition, the SAPS II scores were documented
in all patients on a daily basis. In all patients sepsis-
related death was documented as an outcome para-
meter. Indications for dialysis were the presence of one
or more of the following criteria: refractory hyperkale-
mia, increases of serum creatinine >3 mg/dl and/or of
blood urea nitrogen >100 mg/dl at any given time point,
and signs/symptoms of fluid overload due to diminished
urine output, respectively.
Flow cytometry
For performing flow cytometry, mononuclear cells
(MNCs) were isolated by density gradient centrifuga-
tion using Histopaque-1077 solution (Sigma Diagnos-
tics, St. Louis, MO, USA) from approximately 7.5 ml
of heparinized peripheral blood. Cells were primarily
incubated for one hour on ice with one or more of the
following antibodies: rabbit anti CD133 (ab16518 -
Abcam, Cambridge, UK), mouse anti-human VEGFR2
(FAB 3571F - R&D Systems, Minneapolis, MN, USA),
followed by secondary incubation with PE-conjugated
goat anti-rabbit Fab (VEGFR, 111-116-144 - Jackson
ImmunoResearch Laboratories, Inc., West Grove, PA,
USA) for 30 minutes on ice, respectively. After incuba-
tion, cells were washed with PBS-BSA 1% (w/v). Data
were acquired using a FACScalibur cytometer (Becton
Dickinson, Heidelberg, Germany) equipped with a 488
nm argon laser and a 635 nm red diode laser and ana-
lyzed using CellQuest software (Becton Dickinson, San
Jose, CA, USA). The setup of FACScalibur was per-
formed according to the manufacturer’s instructions
using unstained and single-antibody stained cells. Spe-
cificity of staining was controlled by incubation with
isotype-matched immunoglobulins. To quantify total
peripheral endothelial cells, the numbers of Flk-1 posi-
tive cells, to quantify EPCs, the numbers of CD133/
Flk-1 double-positive cells within the myelomonocytic
cell population were counted [28]. For this purpose,
unstained mononuclear cells were first gated for the
myelomonocytic subpopulation. With regard to the lit-
erature, EPCs (in our study: so-called ‘early outgrowth’
EPCs [9]) are not substantially detectable within the
lymphocytic subpopulation [29]. The gating strategy
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meration of CD34+ cells [30]. Next, single-antibody
stained cells were gated as well in order to recognize
possible unspecific fluorescence signals and in order to
define a threshold between positive and negative sig-
nals. Finally, cells incubated with anti-CD133 and anti-
Flk-1 were measured and in each analysis at least 1.5 ×
10
6 cells were counted. The methodological procedure
is summarized in Figure 1.
Analysis of EPC proliferation (colony-forming units (CFU)
assay)
The assay was performed by using the EndoCult Liquid
Medium Kit
® (StemCell Technologies, Vancouver, BC,
Canada) using the manufacturer’s protocol. MNCs were
resuspended in complete EndoCult medium and seeded
at 5 × 10
6 cells/well on fibronectin-coated tissue culture
plates (BD Biosciences, Rockville, MD, USA). After
48 hours, wells were washed with media and nonadher-
ent cells were co-llected. Nonadherent cells were plated
in their existing media at 10
6 cells/well in 24-well fibro-
nectin-coated tissue culture plates for three days. Only
colonies with at least 20 cells, containing rounded cells
in the middle and elongated cells at the periphery, were
considered as CFU-EC colonies. The numbers of colo-
nies a-ppearing after this period were counted [28]. At
least two members of the laboratory staff evaluated the
numbers of CFU-ECs. They were blinded for the diag-
nosis and status of the investigated patients/controls.
In all patients, the phenotype of cells within the
colonies was determined in more detail. For this
purpose, cells were characterized by the uptake of DiI-
labeled acetylated low density lipoprotein (acLDL)
(Invitrogen, Carlsbad, CA, USA) and binding of FITC-
labeled UE lectin (Sigma Diagnostics, St. Louis, MO,
USA). Cells were first incubated with 10 μg/ml DiI-ac-
LDL at 37°C for 1 hour and later fixed with 2% formal-
dehyde for 10 minutes, followed by incubation with
UE lectin at 37°C for 1 hour. The number of Dil-
acLDL
+/UE lectin
+ cells was counted by laser scanning
microscopy using an inverted fluorescence microscope
IX-71 (Olympus Deutschland GmbH, Hamburg,
Germany) equipped with the appropriate excitation
and emission filters (AHF Analysentechnik, Tuebingen,
Germany).
Enzyme-linked immunosorbent assay (ELISA)
Commercial ELISA tests were purchased for the assess-
ment of vascular endothelial growth factor (VEGF), stro-
mal-derived factor-1 (SDF-1), fibroblast growth factor
( F G F )( a l lf r o mU S C N ,W u h a n ,C h i n a ) ,a n dA n g i o p o i e -
tin-1 and -2 (Alpco, Salem, NH, USA) serum levels.
ELISA tests were performed according to the manufac-
turer’s protocol.
Biochemical and hematological tests
Biochemical and hematological tests were performed in
the Central Laboratories of the University Hospital Göt-
tingen, according to the institutional guidelines.
Statistical analysis
All values are expressed as mean ± SEM. The means of
two populations were compared by the Mann-Whitney
U-Test. In order to compare outcome variables, Fisher’s
test was performed. Correlation analysis was performed
by Spearman’s correlation analysis. Differences between
the two groups were considered significant at P < 0.05,
positive correlation was considered at r = 1.
Results
Patients characteristics
A total of 40 patients with sepsis (17 female, 23 male,
mean age 69 ± 1.9 years) was included in the study. All
patients were recruited from the intensive care unit. Out
of these 40 patients, 25 patients developed acute renal
failure during the course of the disease. In all patients
serum creatinine was measured on a daily basis.
Depending on the overall mean creatinine concentration
12 patients were assigned to the ‘normal creatinine
group’ (creatinine ≤1 mg/dl), the mean serum creatinine
was 0.7 ± 0.05 mg/dl. Twenty-eight patients were
assigned to the ‘high creatinine group’ (creatinine >1
mg/dl), the mean serum creatinine was 2.5 ± 0.28 mg/
dl. Within the ‘high creatinine group’, 15 patients were
male (mean age 72 ± 3.8) and 13 were female (mean
age 69 ± 3.6). The mean AKIN score was significantly
higher in the ‘high creatinine group’ as opposed to the
‘normal creatinine group’ (2.94 ± 0.28 vs. 2.0 ± 0.06, P =
0.02). The frequency of dialysis was 6/12 patients (50%)
in the ‘normal creatinine group’ and 19/28 (67.8%) in
the ‘high creatinine group’. Dialysis frequency did not
significantly differ between the two groups. Survival ana-
lysis revealed that mortality rates as well did not differ
between patients within the ‘normal creatinine group’
and patients within the ‘high creatinine group’.T h e r e
were also no differences in survival between patients
requiring dialysis and patients without the need for dia-
lysis. Patients within the ‘high creatinine group’ showed
significantly higher mean serum levels of uric acid (9.1 ±
2.9 mg/dl vs. 4.5 ± 1.5 mg/dl, P < 0.0001). Patients’ base-
line characteristics are summarized in Table 1.
Circulating endothelial progenitor cells (EPCs)
For quantifying circulating EPCs, we measured CD133
+/
Flk-1
+ myelomonycytic cells. Since CD133 [31], as com-
pared to CD34, has not been shown to be expressed by
mature endothelial cells, we decided to discard CD34 as
a marker of EPCs in our analyses [28]. In a recently
published manuscript on EPCs in hypertensive patients
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+/Flk-1
+ cells (circulating EPCs) in patients with sepsis as compared to healthy controls. For quantification of peripheral
circulating EPCs, all myelomonocytic cells were gated (A). Gated cells were analyzed without antibody staining (B), using the isotype control (C),
and with Flk-1 FITC and CD133 (+secondary antibody) combined. Circulating EPCs in all patients suffering from sepsis and in sepsis patients
within the ‘high creatinine group’ were significantly higher than in healthy controls. There was no statistically significant difference in EPCs
between healthy controls and patients within the ‘normal creatinine group’. (Results as mean ± SEM).
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CD34
+/CD133
+ cells. Although such cells also give rise
to EPCs during further stages of development, they
represent precursors of monocytes as well. In this
regard, enumeration of CD34
+/CD133
+ cells does not
exclusively represent the endothelial lineage. For that
reason, these cells were not quantified in our current
study. The percentages of total circulating endothelial
progenitor cells (CD133
+/Flk-1
+ cells in the percentage
of all myelomonocytic cells) in all patients suffering
from sepsis and in sepsis patients within the ‘high crea-
tinine group’ were significantly higher than in healthy
controls (0.93 ± 0.13% vs. 0.46 ± 0.1%, P =0 . 0 2( %o f
total MNC) and 1.0 ± 0.1% vs. 0.46 ± 0.1%, P =0 . 0 1( %
Table 1 Patients’ characteristics
Patient Mean CRP (mg/dl) SAPS II score Mean serum creatinine (mg/dl) Serum uric acid (mg/dl) Dialysis death
1 187 33 0.36 1.2 + -
2 108 34 0.54 na - -
3 168 32 0.6 4.6 - +
4 116 34 0.6 5.5 + +
5 217 44 0.6 4.5 + +
6 203 31 0.65 6.8 - +
7 319 45 0.69 5.3 + +
8 226 21 0.8 3.7 - -
9 209 45 0.8 3.3 + +
10 179 29 0.9 na - -
11 150 49 0.9 5.6 + +
12 248 27 1 4.1 - -
13 380 28 1.07 6 - -
14 66 48 1.1 7.1 + +
15 193 65 1.11 7.6 + +
16 186 24 1.25 10.3 + -
17 186 37 1.28 6.7 - -
18 173 25 1.32 11.9 - -
19 166 25 1.4 na - -
20 129 29 1.4 na - -
21 519 23 1.41 5.7 - -
22 199 48 1.43 4.4 + -
23 22 36 1.64 11.5 + -
24 127 45 1.7 7 + -
25 104 24 1.9 na - -
26 235 35 2.23 13.9 + +
27 92 42 2.3 na + -
28 75 43 2.5 na + +
29 411 50 2.77 7.2 + -
30 184 28 2.8 16.3 + -
31 419 24 2.97 8.2 - -
32 309 68 3 7.6 + +
33 169 52 3.2 na + +
34 328 34 3.41 8 + -
35 297 54 3.55 13.3 + -
36 110 25 3.63 11.3 + -
37 294 50 4.11 8.2 + +
38 31 45 4.71 9 - +
39 25 29 6.47 11 + -
40 70 24 6.68 7.4 + -
Patients’ characteristics: 12 patients were assigned to the ‘normal creatinine group’, whereas 28 were assigned to the ‘high creatinine group’. There were no
differences in age, SAPS II score, CRP, frequency of dialysis, or survival between the two groups. Patients within the ‘high creatinine group’ showed significantly
higher mean serum levels of uric acid (CRP, C-reactive protein; SAPS II, simplified acute physiology score II; Data as mean ± SEM; na, not available).
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ference in EPCs between healthy controls and patients
within the ‘normal creatinine group’ (Figure 1).
Further analysis revealed that there were no differ-
ences in total peripheral circulating EPCs between
patients requiring dialysis as compared to those without
the need for renal replacement therapy (data not
shown). There were also no differences in circulating
EPCs between patients that had died from sepsis as
compared to patients who had not (data not shown).
Proliferative activity of circulating EPCs (number of
CFU-ECs)
Our previous studies [28] and studies performed by others
[18] had shown that circumstances characterized by
macro- and microvascular damage are associated with
impaired endothelial progenitor cell proliferation. In sep-
sis, both the function and structure of small blood vessels
within the whole organism can severely be affected [1,2].
Therefore, in order to assess the proliferative potential of
the endothelial progenitor cell system in our sepsis
patients, a colony-forming unit (CFU) assay was per-
formed [33]. The so-called CFU assay is a widely accepted
method to evaluate proliferation of ‘early outgrowth’ EPCs
(which were analyzed in our series of experiments). This
has been documented in numerous previous studies
[8-10,13,14,28,33]. The analysis clearly showed lower num-
bers of CFU-ECs (colony-forming unit endothelial cells) in
patients with sepsis than in healthy controls. The differ-
ences appeared independently from the mean serum crea-
tinine levels, subgroup analysis revealed that (I) all patients
with sepsis, (II) patients within the ‘normal creatinine
group’, and (III) patients within the ‘high creatinine group’
showed significant impairment of endothelial progenitor
cell proliferation as compared to healthy controls (11.3 ±
2.3, and 18.5 ± 6.1, and 7.8 ± 1.5 vs. 45.3 ± 7.1, P < 0.0001,
and P = 0.01, and P < 0.0001) (Figure 2).
As for the total circulating EPCs, additional analysis
showed no differences in CFU-ECs between patients
with versus those without dialysis, and no differences in
CFU-ECs between surviving patients and patients with
sepsis-related death.
Correlation analysis
Significant impairment of the EPC system in uremia had
already been documented in 2004. Renal patients had
significantly fewer EPCs than healthy subjects, and ure-
mic serum markedly inhibited EPC differentiation and
functional activity of the cells in vitro [18]. Since in our
study EPC proliferation was decreased in septic patients,
further analysis was performed in order to correlate
serum creatinine levels to both the numbers of colonies
formed in culture (CFU-ECs assay), and the percentages
of peripheral CD133
+/Flk-1
+ cells (circulating EPCs).
There was no correlation between the mean serum crea-
tinine levels and the numbers of colonies or the percen-
tages of circulating EPCs in both the ‘normal creatinine
group’ and the ‘high creatinine group’.
Analysis of proangiogenic cytokine levels
Previous studies showed increased serum levels of
proangiogenic vascular endothelial growth factor
(VEGF) as early as six hours after diagnosing sepsis [25].
In order to assess proangiogenic mediators, we mea-
sured serum levels of VEGF, stromal derived factor-1
(SDF-1), angiopoietin-1 (Ang-1), angiopoietin-2 (Ang-2)
and fibroblast growth factor (FGF) in all patients and in
controls. VEGF and SDF-1 are some of the most potent
known activators of EPCs [13,34], while Ang1-/Tie-2
signaling regulates both the maintenance of vascular
quiescence and promotion of angiogenesis 1 [35].
Increased angiopoietin-2 expression has been shown in
stressed endothelial cells, where it can act as an auto-
crine protective factor of vascular function [36]. Fibro-
blast growth factor (FGF) is currently being evaluated as
a stimulator of angiogenesis [37]. As for cell analyses,
cytokine levels were examined within 12 hours after the
diagnosis of sepsis.
Figure 2 Proliferative activity of peripheral circulating EPCs in
sepsis patients as compared to healthy controls. CFU-ECs
(colony-forming unit endothelial cells) were lower in sepsis patients
than in healthy controls. The differences appeared independently
from the mean serum creatinine levels, subgroup analysis revealed
that (I) all patients with sepsis, and (II) patients within the ‘normal
creatinine group’, and (III) patients within the ‘high creatinine group’
showed significant impairment of endothelial progenitor cell
proliferation as compared to healthy controls. Patients within the
‘high creatinine group’ showed an even more pronounced
reduction in EPC proliferation than patients within the ‘normal
creatinine group’ (Results as mean ± SEM).
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pg/ml vs. 17 ± 3.2 pg/ml, P =0 . 0 3 ) ,a n g i o p o i e t i n - 2
(62,379 ± 6,020 pg/ml vs. 5,892 ± 510 pg/ml, P <
0.0001), and SDF-1 (4,223 ± 360 pg/ml vs. 2,143 ± 117
pg/ml, P < 0.0001) were significantly higher in patients
with sepsis than in healthy controls (Figure 3). Neither
serum levels of Ang-1 nor FGF differed between healthy
controls and patients with sepsis. The serum levels of
VEGF or angiopoietin-2 or SDF-1 did differ between
patients within the ‘high creatinine group’ and the ‘nor-
mal creatinine group’ (data not shown).
Discussion
The aim of the present study was to analyze the
endothelial progenitor cell system in patients suffering
from sepsis with acute impairment of renal function.
We found a significantly higher mean percentage of cir-
culating EPCs in all sepsis patients that were analyzed.
Subgroup analysis showed that patients with a mean
serum creatinine concentration above the normal range
displayed a strong mobilization of CD133
+/Flk-1
+ cells,
whereas, such an increase was absent in sepsis patients
with normal mean creatinine levels. In contrast, EPC
proliferation was severely affected in sepsis patients. As
opposed to previously published results [26], neither
total circulating EPCs (CD133
+/Flk-1
+) nor EPC prolif-
eration differed between surviving patients and patients
with sepsis-related death. Serum levels of proangiogenic
VEGF, SDF-1, and angiopoietin-2 were higher in sepsis
than in healthy controls.
Our data partly conform with observations made by
other investigators. Rafat et al. [26] found significantly
higher numbers of circulating EPCs (defined as CD133
+/CD34
+/Flk-1
+ cells) in sepsis patients than in nonsep-
tic intensive care unit patients and in healthy controls.
In addition, proangiogenic VEGF was also higher in sep-
sis, and EPC percentages correlated with patient survi-
val. The authors concluded that EPC enumeration in
peripheral blood of septic patients might be of benefit in
order to assess the clinical outcome in this condition.
Another study, performed by Becchi and colleagues [25],
also showed EPC mobilization in sepsis with an even
more pronounced increase in severe courses of the dis-
ease. Nevertheless, in the latter study EPCs were solely
defined by the expression of CD34. This approach is
potentially critical since CD34 is substantially expressed
on mature endothelial cells and on different types of
hematopoietic precursor cells as well [38]. This might
explain the significant higher average percentages of
EPCs reported in the study [25]. Our analysis did not
show different percentages of circulating EPCs between
dead and surviving patients. The reason for this discre-
pancy remains speculative, although it seems possible
that the narrower time frame in which blood samples
Figure 3 Serum levels of VEGF, SDF-1, and Ang-2 were dramatically higher in sepsis patients than in healthy controls.A n a l y s i sw a s
performed within 6 to 12 hours after diagnosis of the disease (Results as mean ± SEM).
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sepsis as opposed to 48 hours in the study by Rafat and
colleagues [26]) can account for the different results.
Nevertheless, the most intriguing findings in our study
were related to circulating EPCs and EPC proliferation
in patients with high mean serum creatinine. Different
studies have reported reduced numbers and impaired
function of EPCs in chronic renal insufficiency
[18,39,40]. These observations mirror the state of gener-
alized endothelial dysfunction in chronic kidney disease
(CKD). Mechanisms responsible for EPC suppression,
thereby, involve deleterious effects of different sub-
stances such as parathyroid hormone (PTH), IL-6,
homocysteine, and p-cresol [40]. The patients that were
analyzed in our study displayed higher percentages of
circulating EPCs, which was in line with previously pub-
lished data from patients with sepsis [25,26], but
opposed to chronic renal failure, acute impairment of
renal function did not significantly suppress such an
EPC mobilization. Patients within the ‘high creatinine
group’, in contrast, showed an even more pronounced
elevation of CD133
+/Flk-1
+ cells. The mobilization of
EPCs could be explained as a result of higher mean
serum levels of three mediators, all of them known to
be involved in stimulating EPC migration (SDF-1 [13],
angiopoietin-2 [41], and VEGF [34]). Thus, the influ-
ence of acute renal malfunction seems to have a differ-
ent impact on the EPC system than CKD. A complete
lack of any impact can be denied, since especially
patients within the ‘high creatinine group’ showed a sig-
nificantly stronger EPC mobilization than patients
within the ‘normal creatinine group’. Pronounced sup-
pression of EPC proliferation might result from a begin-
ning accumulation of endogenous toxins as this is
thought to be responsible for EPC suppression in CKD
[18]. The higher percentages of circulating EPCs in
patients within the ‘high creatinine group’ are of parti-
cular interest since these patients did not display higher
average serum levels of the proangiogenic cytokines that
were measured. Therefore, acute renal dysfunction pos-
sibly activates ‘vascular danger signals’ in order to acti-
vate endogenous repair mechanisms. A number of
studies showed that EPCs are potent mediators of renal
repair after ischemia [16,23,24]. It has been documented
that acute renal ischemia, since it is the most frequent
cause of acute renal failure in the intensive care unit,
dramatically mobilizes EPCs from their respective
niches. This mobilization occurs as early as three hours
after hypoperfusion [16]. A very potent endogenous
mediator of EPCs is uric acid which is rapidly released
into systemic circulation after reperfusion has been
initiated [23]. Uric acid-mediated EPC mobilization
results from degranulation of Weibel-Palade bodies and
this event requires the presence of toll-like receptor 4
(TLR 4) [41]. Since TLR 4 acts as the receptor that sig-
nals LPS bioactivity in sepsis [42], the TLR4/uric acid/
Weibel-Palade axis might work as the proposed ‘vascu-
lar danger signals’ that agonizes EPCs in the bone mar-
row to migrate into the circulation. Patients within the
‘high creatinine group’ showed significantly higher
serum levels of uric acid, which is in line with the pro-
posed hypothesis of uric acid mediated EPC mobiliza-
tion in sepsis-associated acute renal dysfunction.
Nevertheless, the possible role of uric acid as endogen-
ous stimulator of EPC mobilization in the setting of
sepsis can only be speculated at the moment and
further analysis will have to be performed in order to
further confirm this theory.
In summary, we present the first data on EPC mobili-
zation and proliferation in sepsis with acute impairment
of renal function. Acute renal dysfunction, via increasing
serum concentrations of endogenous toxins, augments
sepsis-associated EPC mobilization and worsens sup-
pression of EPC proliferation. The molecular mechan-
isms responsible for increased cell mobilization involve
increased production and release of proangiogenic sub-
stancies. In addition, regarding the literature on the
mechanisms of post-ischemic EPC mobilization and
regarding systemic concentrations of uric acid a pro-
posed ‘vascular danger cascade’ might involve release of
uric acid and actions of TLR 4. This possible relation-
ship has to be analyzed in further studies.
Conclusions
In conclusion, sepsis is associated with significant
impairment of the endothelial progenitor cell system.
This is reflected by increased EPC numbers, increased
concentrations of proangiogenic mediators, and reduced
proliferative capacity of the cells, respectively. While
these events occur independently from the frequency of
dialysis and from patient survival, increased serum levels
of uric acid could potentially play a role in the stimula-
tion of EPC mobilization in sepsis patients with higher
average creatinine levels.
Key messages
￿ The endothelial progenitor cell system is severely
affected in sepsis.
￿ Sepsis patients with higher mean serum creatinine
levels, due to acute kidney injury, show an even
more pronounced mobilization of EPCs.
￿ Alterations of the EPC system in sepsis occur inde-
pendently from the frequency of dialysis and inde-
pendently from patient survival.
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